{"id":20934,"date":"2023-01-27T17:43:00","date_gmt":"2023-01-27T12:13:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=20934"},"modified":"2023-05-22T12:16:31","modified_gmt":"2023-05-22T06:46:31","slug":"lupus-nephritis-treatment-outlook","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-treatment-outlook","title":{"rendered":"Lupus Nephritis: A SILENT but SEVERE Systemic Lupus Erythematosus Manifestation"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a0e2a7a1a2ae\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a0e2a7a1a2ae\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-treatment-outlook\/#What_are_the_currently_available_lupus_nephritis_treatment_options_for_patients\" >What are the currently available lupus nephritis treatment options for patients?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-treatment-outlook\/#What_is_the_unmet_need_for_the_current_lupus_nephritis_treatment_market\" >What is the unmet need for the current lupus nephritis treatment market?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-treatment-outlook\/#Scope_of_upcoming_lupus_nephritis_therapies\" >Scope of upcoming lupus nephritis therapies<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-treatment-outlook\/#FAQs\" >FAQs<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Lupus Nephritis (LN) is the most feared and common complication of systemic lupus erythematosus (SLE) and is responsible for the major share of morbidity and mortality of this disease. It affects around half of the systemic lupus erythematosus patients, and in <strong>~35%<\/strong> of patients, lupus nephritis is the presenting feature at the time of systemic lupus erythematosus diagnosis. The disease is characterized by accumulating immune complexes in glomeruli and often an inflammatory response in all kidney compartments. Over time inflammation leads to chronic damage of the renal parenchyma and loss of kidney function.<\/p>\n\n\n\n<p>Signs and lupus nephritis symptoms vary highly and may differ for everyone. The most frequent lupus nephritis symptoms include joint pain or swelling, muscle pain, or fever with no known cause. Clinical signs such as hematuria and proteinuria suggest lupus nephritis in <a href=\"https:\/\/www.delveinsight.com\/blog\/systemic-lupus-erythematosus-market\">patients with systemic lupus erythematosus<\/a>. Kidney biopsy remains the only confirmatory test for establishing the lupus nephritis diagnosis. Active surveillance is recommended in systemic lupus erythematosus patients at high risk of kidney involvement (males, juvenile lupus onset, and serologically active disease).<\/p>\n\n\n\n<p>Among the adults, systemic lupus erythematosus patients <strong>~40\u201350%<\/strong> develop lupus nephritis. However, it has been widely known that juvenile onset of lupus results in a more aggressive disease, and <strong>~60\u201380%<\/strong> of juvenile systemic lupus erythematosus patients develop lupus nephritis.&nbsp;<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><strong>As per a recent analysis by DelveInsight, in the 7MM, the total <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/lupus-nephritis-epidemiology-forecast\"><strong>prevalent cases of lupus nephritis<\/strong><\/a><strong> in 2021 were approximately 260K cases. The growth in the lupus nephritis treatment market can be attributed to the aging population and increased exposure to pollutants, industrial agents, UV light, etc. The increasing use of hormonal drugs has also been identified as a risk factor among females.<\/strong><\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-are-the-currently-available-lupus-nephritis-treatment-options-for-patients\"><span class=\"ez-toc-section\" id=\"What_are_the_currently_available_lupus_nephritis_treatment_options_for_patients\"><\/span><strong>What are the currently available lupus nephritis treatment options for patients?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/lupus-nephritis-market\">Lupus nephritis treatment recommendations<\/a> are dependent on the degree of histological kidney involvement. Currently, patients with Class I\/II (ISN\/RPS 2003 criteria) are mostly monitored and do not need immunosuppressants. Patients with Class VI LN have \u226590% glomerular sclerosis and are unlikely to respond to medical therapy. For such patients, dialysis or complete renal replacement are the only available options. Patients with Class III\/IV \u00b1 V LN (also known as proliferative LN \u00b1 membranous nephropathy), which account for ~80% of all lupus nephritis patients, are recommended pharmacological therapy<\/p>\n\n\n\n<p>For decades, rheumatologists and nephrologists have had to manage <a href=\"https:\/\/www.delveinsight.com\/report-store\/lupus-nephritis-epidemiology-forecast\">lupus nephritis patients<\/a> solely through immunosuppressants and corticosteroids. The lupus nephritis treatment armamentarium was finally expanded by <a href=\"https:\/\/www.delveinsight.com\/report-store\/benlysta-belimumab-drug-insight-market-forecast\"><strong>GSK\u2019s Benlysta (belimumab)<\/strong><\/a> approval in 2020. Benlysta became the first drug approved for managing adult patients with active lupus nephritis who receive standard therapy.<\/p>\n\n\n\n<p>In 2021, <strong>Aurinia Pharmaceutical<\/strong> gained US FDA approval for <a href=\"https:\/\/www.delveinsight.com\/report-store\/lupkynis-market-drug-insight-and-market-forecast\"><strong>Lupkynis (voclosporin)<\/strong><\/a>, a calcineurin inhibitor,&nbsp; in combination with a background immunosuppressive therapy regimen to treat adult patients with lupus nephritis for Class III, IV-S, IV-G (\u00b1V) (ISN\/RPS 2003 criteria).<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/30105541\/Lupus-Nephritis-Market-Assessment.png\" alt=\"Lupus Nephritis Market Assessment\" class=\"wp-image-20975\" width=\"700\" height=\"391\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/30105541\/Lupus-Nephritis-Market-Assessment.png 700w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/30105541\/Lupus-Nephritis-Market-Assessment-300x168.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/30105541\/Lupus-Nephritis-Market-Assessment-150x84.png 150w\" sizes=\"(max-width: 700px) 100vw, 700px\" \/><figcaption class=\"wp-element-caption\"><strong>Lupus Nephritis Market Scenario<\/strong><\/figcaption><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_the_unmet_need_for_the_current_lupus_nephritis_treatment_market\"><\/span><strong>What is the unmet need for the current lupus nephritis treatment market?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Lupus nephritis remains a kidney disease with significant unmet medical needs despite extensive clinical and translational research. These include<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Novel diagnostic biomarkers for early diagnosis<\/li>\n\n\n\n<li>Therapeutic options for patients who do not respond to or are unfit for immunosuppressive therapies<\/li>\n\n\n\n<li>Steroid\/immunosuppressant-sparing drugs can provide sustained remission<\/li>\n\n\n\n<li>Improve the design of randomized clinical trials so that effective drugs demonstrate efficacy<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Scope_of_upcoming_lupus_nephritis_therapies\"><\/span><strong>Scope of upcoming lupus nephritis therapies<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Although there has been a history of high trial failure rates in lupus nephritis, the approval of <strong>Benlyta and Lupkynis<\/strong> has given hope of light and significant <a href=\"https:\/\/www.delveinsight.com\/report-store\/lupus-nephritis-pipeline-insight\">lupus nephritis pipeline<\/a> activity. Here is a list of major key players and competitors in the lupus nephritis treatment market:<\/p>\n\n\n\n<div>\n<table style=\"border:none; border-collapse:collapse; table-layout:fixed; width:624px\" width=\"NaN\">\n\t<colgroup>\n\t\t<col>\n\t\t<col>\n\t<\/colgroup>\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:top; background-color:#cc223d; padding:7px 7px 7px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000\" width=\"NaN\">\n\t\t\t<p style=\"line-height:1.2; text-align:center\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#ffffff\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Upcoming Therapies and Key Companies<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:top; background-color:#cc223d; padding:7px 7px 7px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000\" width=\"NaN\">\n\t\t\t<p style=\"line-height:1.2; text-align:center\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#ffffff\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Key Insights<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:top; background-color:#f2f2f2; padding:7px 7px 7px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000\" width=\"NaN\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Gazyva (Obinutuzumab): Roche<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:top; padding:7px 7px 7px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000\" width=\"NaN\">\n\t\t\t<ul>\n\t\t\t\t<li aria-level=\"1\" style=\"list-style-type:disc\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Obinutuzumab is a humanized, monoclonal type II CD20 antibody marketed for chronic lymphocytic leukemia and follicular lymphoma.<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/li>\n\t\t\t\t<li aria-level=\"1\" style=\"list-style-type:disc\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Currently, the drug is being evaluated in two Phase III (NCT04221477, NCT04702256) for adults.<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/li>\n\t\t\t\t<li aria-level=\"1\" style=\"list-style-type:disc\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Received Breakthrough Therapy Designation by the US FDA for Lupus Nephritis.<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/li>\n\t\t\t<\/ul>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:top; background-color:#f2f2f2; padding:7px 7px 7px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000\" width=\"NaN\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Ianalumab (VAY736): Novartis\/MorphoSys<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:top; padding:7px 7px 7px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000\" width=\"NaN\">\n\t\t\t<ul>\n\t\t\t\t<li aria-level=\"1\" style=\"list-style-type:disc\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Subcutaneously administered BAFF-R antagonist.<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/li>\n\t\t\t\t<li aria-level=\"1\" style=\"list-style-type:disc\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Currently, in Phase III (NCT05126277) trial for the treatment of adults.<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/li>\n\t\t\t<\/ul>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:top; background-color:#f2f2f2; padding:7px 7px 7px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000\" width=\"NaN\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Cosentyx (secukinumab): Novartis<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:top; padding:7px 7px 7px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000\" width=\"NaN\">\n\t\t\t<ul>\n\t\t\t\t<li aria-level=\"1\" style=\"list-style-type:disc\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Novartis is testing its IV-administered IL-17A antagonist, marketed for multiple autoimmune diseases (Plaque psoriasis, ankylosing spondylitis, axial spondyloarthritis etc.) in adults with Class III\/IV \u00b1 V LN.<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/li>\n\t\t\t\t<li aria-level=\"1\" style=\"list-style-type:disc\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Currently, the drug is being evaluated in two Phase III (NCT05232864, NCT04181762) clinical trials.<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/li>\n\t\t\t<\/ul>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:top; background-color:#f2f2f2; padding:7px 7px 7px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000\" width=\"NaN\">\n\t\t\t<p style=\"line-height:1.2\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Saphnelo (anifrolumab): AstraZeneca<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:top; padding:7px 7px 7px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000\" width=\"NaN\">\n\t\t\t<ul>\n\t\t\t\t<li aria-level=\"1\" style=\"list-style-type:disc\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">It is an intravenously administered INF-\u03b1\/\u03b2 receptor antagonist<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/li>\n\t\t\t\t<li aria-level=\"1\" style=\"list-style-type:disc\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">In Phase II (TULIP-LN1; NCT02547922) trial, the drug was not able to meet the PE (Urine Protein to Creatinine Ratio (UPCR); however, the drug was associated with numeric improvements across all clinical endpoints vs. placebo.<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/li>\n\t\t\t\t<li aria-level=\"1\" style=\"list-style-type:disc\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">AstraZeneca is hopeful that higher dosing might be effective and has initiated a Phase III trial (NCT05138133) for the treatment in adult subjects with Class III\/IV \u00b1 V active proliferative LN. The trial was expected to start in H2 2022.<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/li>\n\t\t\t<\/ul>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t<\/tbody>\n<\/table>\n<\/div>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Other notable players like <strong>Kezar Life Sciences (KZR-616 in PI\/II), Johnson &amp; Johnson (Nipocalimab and Guselkumab in PII), Novartis (CFZ533 [iscalimab] in PII), Boehringer Ingelheim (BI 655064 in PII), AstraZeneca (Ravulizumab and ALXN2050 [Vemircopan] in PII), Biocon\/Equillium (Itolizumab in PI), and Omeros Corporation (OMS721 [narsoplimab] in PII)<\/strong> are enriching the robust lupus nephritis pipeline.<\/p>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/lupus-nephritis-market\">lupus nephritis treatment market<\/a> is expected to grow at a<strong> CAGR of 8.4%<\/strong> from 2021 and generate approx. <strong>USD 3 billion<\/strong> in revenue in the seven major markets (the United States, Germany, France, Italy, Spain, UK, and Japan) by 2032 owing to the uptake of <strong>Lupkynis (voclosporin) and Benlysta (belimumab)<\/strong>, expected approvals of the <a href=\"https:\/\/www.delveinsight.com\/report-store\/lupus-nephritis-pipeline-insight\">emerging lupus nephritis therapies<\/a>.<\/p>\n\n\n\n<p>Less competitive scenarios, increasing government initiatives to create public awareness, and increasing systemic lupus erythematosus patients will also positively impact the growth of the lupus nephritis treatment market.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/lupus-nephritis-market\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/27112306\/Lupus-nephritis-market-outlook-1024x256.png\" alt=\"Lupus nephritis market outlook\" class=\"wp-image-20965\" width=\"1024\" height=\"256\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/27112306\/Lupus-nephritis-market-outlook-1024x256.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/27112306\/Lupus-nephritis-market-outlook-300x75.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/27112306\/Lupus-nephritis-market-outlook-150x38.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/27112306\/Lupus-nephritis-market-outlook-768x192.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/27112306\/Lupus-nephritis-market-outlook-1536x384.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/27112306\/Lupus-nephritis-market-outlook-1568x392.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/27112306\/Lupus-nephritis-market-outlook.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><strong>FAQs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1674630459869\"><strong class=\"schema-faq-question\"><strong>1. What is lupus nephritis?<\/strong><\/strong> <p class=\"schema-faq-answer\">Lupus Nephritis (LN) is the most feared and common complication of systemic lupus erythematosus (SLE) and is responsible for the major share of morbidity and mortality of this disease.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1674630474035\"><strong class=\"schema-faq-question\"><strong>2. What are the lupus nephritis symptoms?<\/strong><\/strong> <p class=\"schema-faq-answer\">Signs and lupus nephritis symptoms vary highly and may differ for everyone. The most frequent lupus nephritis symptoms include joint pain or swelling, muscle pain, or fever with no known cause.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1674630486884\"><strong class=\"schema-faq-question\"><strong>3. How is lupus nephritis diagnosed?<\/strong><\/strong> <p class=\"schema-faq-answer\">Kidney biopsy remains the only confirmatory test for establishing the lupus nephritis diagnosis. Active surveillance is recommended in systemic lupus erythematosus patients at high risk of kidney involvement (males, juvenile lupus onset, and serologically active disease).<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1674630501677\"><strong class=\"schema-faq-question\"><strong>4. What are the current lupus nephritis treatment options?<\/strong><\/strong> <p class=\"schema-faq-answer\">Lupus nephritis treatment recommendations are dependent on the degree of histological kidney involvement. Currently, patients with Class I\/II (ISN\/RPS 2003 criteria) are mostly monitored and do not need immunosuppressants. Patients with Class VI LN have \u226590% glomerular sclerosis and are unlikely to respond to medical therapy.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1674630516177\"><strong class=\"schema-faq-question\"><strong>5. Which pharma companies are working in the lupus nephritis treatment market?<\/strong><\/strong> <p class=\"schema-faq-answer\">Leading companies such as Aurinia Pharmaceuticals, Roche, AstraZeneca, Boehringer Ingelheim, Novartis, and others are developing therapies for lupus nephritis treatment.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Lupus Nephritis (LN) is the most feared and common complication of systemic lupus erythematosus (SLE) and is responsible for the major share of morbidity and mortality of this disease. It affects around half of the systemic lupus erythematosus patients, and in ~35% of patients, lupus nephritis is the presenting feature at the time of systemic [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":20970,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":4,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[1555,6248,6250,17782,6249,721],"industry":[17225],"therapeutic_areas":[17227],"class_list":["post-20934","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-lupus-drug","tag-lupus-nephritis","tag-lupus-nephritis-market","tag-lupus-nephritis-pipeline","tag-lupus-nephritis-therapy","tag-systemic-lupus-erythematosus","industry-pharmaceutical","therapeutic_areas-immunological-and-autoimmune-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Lupus Nephritis Treatment Scenario and Market Outlook<\/title>\n<meta name=\"description\" content=\"Dynamics of lupus nephritis treatment market is expected to change in coming years as 20+ companies are exploring the therapeutics segment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-treatment-outlook\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lupus Nephritis Treatment Scenario and Market Outlook\" \/>\n<meta property=\"og:description\" content=\"Dynamics of lupus nephritis treatment market is expected to change in coming years as 20+ companies are exploring the therapeutics segment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-treatment-outlook\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-27T12:13:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-22T06:46:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/27174046\/Lupus-Nephritis-Treatment-Market-Outlook-and-Emerging-Therapies.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lupus Nephritis Treatment Scenario and Market Outlook","description":"Dynamics of lupus nephritis treatment market is expected to change in coming years as 20+ companies are exploring the therapeutics segment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-treatment-outlook","og_locale":"en_US","og_type":"article","og_title":"Lupus Nephritis Treatment Scenario and Market Outlook","og_description":"Dynamics of lupus nephritis treatment market is expected to change in coming years as 20+ companies are exploring the therapeutics segment.","og_url":"https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-treatment-outlook","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2023-01-27T12:13:00+00:00","article_modified_time":"2023-05-22T06:46:31+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/27174046\/Lupus-Nephritis-Treatment-Market-Outlook-and-Emerging-Therapies.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-treatment-outlook","url":"https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-treatment-outlook","name":"Lupus Nephritis Treatment Scenario and Market Outlook","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-treatment-outlook#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-treatment-outlook#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/27174046\/Lupus-Nephritis-Treatment-Market-Outlook-and-Emerging-Therapies.png","datePublished":"2023-01-27T12:13:00+00:00","dateModified":"2023-05-22T06:46:31+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Dynamics of lupus nephritis treatment market is expected to change in coming years as 20+ companies are exploring the therapeutics segment.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-treatment-outlook#faq-question-1674630459869"},{"@id":"https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-treatment-outlook#faq-question-1674630474035"},{"@id":"https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-treatment-outlook#faq-question-1674630486884"},{"@id":"https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-treatment-outlook#faq-question-1674630501677"},{"@id":"https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-treatment-outlook#faq-question-1674630516177"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-treatment-outlook"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-treatment-outlook#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/27174046\/Lupus-Nephritis-Treatment-Market-Outlook-and-Emerging-Therapies.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/27174046\/Lupus-Nephritis-Treatment-Market-Outlook-and-Emerging-Therapies.png","width":772,"height":482,"caption":"Lupus Nephritis Treatment Market Outlook and Emerging Therapies"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-treatment-outlook#faq-question-1674630459869","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-treatment-outlook#faq-question-1674630459869","name":"1. What is lupus nephritis?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Lupus Nephritis (LN) is the most feared and common complication of systemic lupus erythematosus (SLE) and is responsible for the major share of morbidity and mortality of this disease.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-treatment-outlook#faq-question-1674630474035","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-treatment-outlook#faq-question-1674630474035","name":"2. What are the lupus nephritis symptoms?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Signs and lupus nephritis symptoms vary highly and may differ for everyone. The most frequent lupus nephritis symptoms include joint pain or swelling, muscle pain, or fever with no known cause.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-treatment-outlook#faq-question-1674630486884","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-treatment-outlook#faq-question-1674630486884","name":"3. How is lupus nephritis diagnosed?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Kidney biopsy remains the only confirmatory test for establishing the lupus nephritis diagnosis. Active surveillance is recommended in systemic lupus erythematosus patients at high risk of kidney involvement (males, juvenile lupus onset, and serologically active disease).","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-treatment-outlook#faq-question-1674630501677","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-treatment-outlook#faq-question-1674630501677","name":"4. What are the current lupus nephritis treatment options?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Lupus nephritis treatment recommendations are dependent on the degree of histological kidney involvement. Currently, patients with Class I\/II (ISN\/RPS 2003 criteria) are mostly monitored and do not need immunosuppressants. Patients with Class VI LN have \u226590% glomerular sclerosis and are unlikely to respond to medical therapy.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-treatment-outlook#faq-question-1674630516177","position":5,"url":"https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-treatment-outlook#faq-question-1674630516177","name":"5. Which pharma companies are working in the lupus nephritis treatment market?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Leading companies such as Aurinia Pharmaceuticals, Roche, AstraZeneca, Boehringer Ingelheim, Novartis, and others are developing therapies for lupus nephritis treatment.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/27174046\/Lupus-Nephritis-Treatment-Market-Outlook-and-Emerging-Therapies-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">lupus drug<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Lupus nephritis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Lupus nephritis market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Lupus Nephritis Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Lupus nephritis therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Systemic Lupus Erythematosus<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">lupus drug<\/span>","<span class=\"advgb-post-tax-term\">Lupus nephritis<\/span>","<span class=\"advgb-post-tax-term\">Lupus nephritis market<\/span>","<span class=\"advgb-post-tax-term\">Lupus Nephritis Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Lupus nephritis therapy<\/span>","<span class=\"advgb-post-tax-term\">Systemic Lupus Erythematosus<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 3 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Jan 27, 2023","modified":"Updated on May 22, 2023"},"absolute_dates_time":{"created":"Posted on Jan 27, 2023 5:43 pm","modified":"Updated on May 22, 2023 12:16 pm"},"featured_img_caption":"Lupus Nephritis Treatment Market Outlook and Emerging Therapies","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/20934","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=20934"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/20934\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/20970"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=20934"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=20934"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=20934"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=20934"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=20934"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}